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Abstract
Background: Mendelian randomization studies have so far restricted attention to linear
associations relating the genetic instrument to the exposure, and the exposure to the out-
come. In some cases, however, observational data suggest a non-linear association
between exposure and outcome. For example, alcohol consumption is consistently re-
ported as having a U-shaped association with cardiovascular events. In principle,
Mendelian randomization could address concerns that the apparent protective effect of
light-to-moderate drinking might reflect ‘sick-quitters’ and confounding.
Methods: The Alcohol-ADH1B Consortium was established to study the causal effects of
alcohol consumption on cardiovascular events and biomarkers, using the single nucleo-
tide polymorphism rs1229984 in ADH1B as a genetic instrument. To assess non-linear
causal effects in this study, we propose a novel method based on estimating local aver-
age treatment effects for discrete levels of the exposure range, then testing for a linear
trend in those effects. Our method requires an assumption that the instrument has the
same effect on exposure in all individuals. We conduct simulations examining the
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robustness of the method to violations of this assumption, and apply the method to the
Alcohol-ADH1B Consortium data.
Results: Our method gave a conservative test for non-linearity under realistic violations
of the key assumption. We found evidence for a non-linear causal effect of alcohol intake
on several cardiovascular traits.
Conclusions:We believe our method is useful for inferring departure from linearity when
only a binary instrument is available. We estimated non-linear causal effects of alcohol
intake which could not have been estimated through standard instrumental variable
approaches.
Key words: Mendelian randomization, instrumental variables, causal inference, local average treatment effects,
alcohol consumption, cardiovascular disease
Introduction
Recent years have seen an increasing number of Mendelian
randomization (MR) analyses that examine causal rela-
tionships between heritable exposures, such as levels of cir-
culating biomarkers, and outcomes such as multifactorial
diseases, for example coronary heart disease and type 2
diabetes.1,2,3 In principle, MR reduces problems of con-
founding and abolishes reverse causation by using a genetic
proxy for the exposure in an instrumental variable (IV)
analysis.4
To date, applications of MR have been limited to lin-
ear (or log-linear) models for the associations between
gene and exposure and between exposure and outcome.
In part this is because linear models have a natural
interpretation which may be useful even if the true rela-
tionship is non-linear.5 Furthermore, many of the associ-
ations between genetic variants and complex traits
discovered to date have appeared to be linear.6
However, in learning about causal relationships it is
clearly of value to identify and characterize non-linear ef-
fects when they are present, bearing in mind that the ex-
istence and extent of such relationships may depend on
the measurement scale. In particular, non-linear associ-
ations may translate into opposing effects (protective as
well as harmful) according to the level of the exposure.
Such opposing effects have been observed in many obser-
vational studies examining the relationship between alco-
hol consumption and cardiovascular events.7 Specifically,
light-to-moderate levels of alcohol consumption have
been associated with decreased risk of cardiovascular
events relative to non-drinkers, with increased risk only
occurring at higher levels of consumption. This apparent
protective effect of light-to-moderate alcohol consump-
tion could be explained by several different mechanisms,
and corresponding ‘J’- or ‘U’-shaped associations have
been observed with cardiovascular risk factors including
low-density lipoprotein particles,8 abdominal adiposity,9
C-reactive protein (CRP),10,11 and triglycerides (TG).12
Similar observational associations were seen in our ear-
lier analyses of ADH1B Consortium data (Holmes et al.,
Supplementary Appendix, Figure S313).
As these observational findings suggest that light-
to-moderate consumption may be cardio-protective, it is of
great interest to consumers, suppliers and policy makers to
Key Messages
• Mendelian randomization studies have so far restricted attention to linear associations relating the genetic instrument
to the exposure, and the exposure to the outcome, but this may not always be appropriate. For example, alcohol con-
sumption is consistently reported as having a U-shaped association with cardiovascular events in observational
studies.
• We propose a novel Mendelian randomization method based on estimating local average treatment effects for dis-
crete levels of the exposure range, then testing for a linear trend in those effects.
• Our method gave a conservative test for non-linearity under realistic violations of the key assumption in simulations,
and we believe our method is useful for inferring departure from linearity when only a binary instrument is available.
• We found evidence for a non-linear causal effect of alcohol intake on several cardiovascular traits in the Alcohol-
ADH1B Consortium, using the single nucleotide polymorphism rs1229984 in ADH1B as a genetic instrument.
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establish whether this pattern is causal. Confounding is
plausible, since socioeconomic groups that drink moder-
ately may have other lifestyle factors that directly lead to
lower rates of disease,14 and the relationship between con-
founders and alcohol may themselves be non-linear.
Evidence for reverse causation is also well established,
with those developing ill health or commencing medication
more likely to reduce or quit alcohol consumption (the
‘sick-quitters’ phenomenon).15,16
Alcohol consumption is influenced by genetic vari-
ants that affect alcohol metabolism. Heritability of
alcoholism has been estimated at 40–60%, and variants in
ALDH2, ADH1B and ADH1C that encode for liver en-
zymes have been associated with decreased intake, via
increased metabolism of alcohol to acetaldehyde or
decreased acetaldehyde clearance, both leading to unpleas-
ant side effects.17 In particular, ADH1B has been shown to
be robustly associated with alcohol consumption18,19 and
has been used in MR analyses to explore the causal effect
of alcohol consumption on coronary heart disease risk
factors.20
We recently established a large consortium (the
‘Alcohol-ADH1B Consortium’) of genetic association
studies of European descent that used a single nucleotide
polymorphism (SNP) in ADH1B, rs1229984, as the instru-
ment to assess the impact of alcohol consumption on car-
diovascular events and risk factors.13 This consortium
showed that carrying the rs1229984 A-allele was associ-
ated with non-drinking, lower alcohol consumption and
lower incidence of binge drinking, which expands the pre-
vious associations of this variant with alcohol traits.13
Using a genetic association analysis, the consortium also
showed that ADH1B carriers had a more favourable car-
diovascular profile and a reduced risk of coronary heart
disease (CHD).13 However, because of the existing litera-
ture on non-linear effects of alcohol consumption on car-
diovascular events and the lack of appropriate methods to
account for non-linear associations within IV analyses, we
did not initially conduct an MR analysis in the Alcohol-
ADH1B Consortium.
Approaches have been proposed for non-linear IV ana-
lysis in the econometric literature,21–23 but they cannot be
used in this context because we use a single SNP as the IV.
In the present paper, we develop new methods to conduct
non-linear IV analysis using a single binary instrument,
and also evaluate the impact of the key assumption of our
method. We then apply our method to the data from the
Alcohol-ADH1BConsortium to assess whether the causal
effect of alcohol on cardiovascular traits is indeed non-lin-
ear and whether this implies a non-zero optimal level of
consumption for cardiovascular health, which has clear
implications for public health.
Material and methods
Data
The Alcohol-ADH1B Consortium is a collaboration of
studies in which the associations between an allele of the
ADH1B gene and 22 cardiovascular biomarkers and risks
of coronary heart disease, stroke and type 2 diabetes have
been examined.13 Here our analyses are restricted to the
22 studies (18 cohorts, 2 nested case-control studies, 1
randomized trial and1 case-control study) with individual
participant data originating from Europe (n¼ 16) and
North America (n¼ 6). Analysis was restricted to individ-
uals of European descent.13
The principal alcohol trait was weekly volume of alco-
hol in British units [1 British unit is equivalent to 0.57 US
units or 10 ml (7.9 g) ethanol], which we derived using
questionnaire data from each study. For studies in which
this variable was not already present, we either calculated
weekly volume of alcohol by summing over the individual
components of beverage-specific drink questions (available
in 20 of the 22 studies), or by converting alcohol recorded
in g/week into British units.13 The units/week were
log-transformed, after incrementing by one to allow for
individuals reporting zero weekly alcohol consumption,
resulting in a normally distributed phenotype that had
homoscedastic residual error after regressing on the
ADH1B genotype.
Here we considered a subset of outcomes for which a
non-linear causal association was either postulated
from subject-matter knowledge, or suggested by the obser-
vational data available from the Alcohol-ADH1B
Consortium (all P< 0.001 for the quadratic term in a
quadratic model): systolic blood pressure (SBP), non high-
density lipoprotein cholesterol (non-HDL-C),TG, high-
density lipoprotein cholesterol (HDL-C), body mass index
(BMI), waist circumference (WC), CRP and interleukin 6
(IL-6). Outcomes were log-transformed towards normality
when appropriate (TG, CRP and IL-6).
The rs1229984 polymorphism in ADH1B was directly
genotyped in all studies and coded as 0/1 according to the
carriage of at least one minor allele. This coding was
adopted owing both to the low prevalence of the
rs1229984A-allele (average carriage of rs1229984A-alleles
in the analysis sample: 7.7%) and the stronger association
observed with alcohol dependence and other alcohol-
related traits under a dominant model compared with a re-
cessive model.24
Full details of participating studies, phenotype defin-
ition and genotyping are reported elsewhere13 and are
summarized in Table S1 in the Supplementary data, avail-
able at IJE online.
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Linear instrumental variable analysis
We used standard two-stage least squares (2SLS) to estimate
a linear causal effect of log(weekly units of alcoholþ1)
(hereafter, log-alcohol) on continuous cardiovascular out-
comes. That is, we fitted the first-stage linear regression
xi ¼ bXGgi þ b0XZzi þ eXi
where xi is log-alcohol for subject i, gi is a binary code for
the rs1229984 genotype, zi is a vector of covariates and eXi
are residual errors assumed to be independent and identi-
cally distributed with mean zero. Regression coefficients
bXG and bXZ were estimated as fixed effects. We used the
fitted model to predict x^i then estimated the alcohol-out-
come association bYX from the regression
yi ¼ bYXx^i þ b0YZzi þ eYi
where yi is the continuous cardiovascular outcome for sub-
ject i and eYi are residual errors assumed to be independent
and identically distributed with mean zero. A 95% confi-
dence interval (CI) for b^YX was derived by nesting the
2SLS within a bootstrap resampling procedure using
10 000 bootstrap samples. As covariates we included in
both regressions a fixed effect for each study and fixed ef-
fects for age and sex.
Non-linear causal effects
To test for non-linearity of the causal X-Y association we
consider local average treatment effects (LATEs) in sub-
groups of X.25 First we coarsen X into a discrete and
rescaled variable X ¼ XbXG
j k
with finite support, assumed
without loss of generality to be f0;…; Jg for fixed J. G is
an instrument for X if it is independent of the remainder
XX (see Figure 1); this is not generally true but it can
be tested in applications. Under linear models we can ob-
tain an estimate of the causal effect of X on Y, but this ef-
fect can also be represented as a weighted sum of
LATEs,25,26 which are causal effects among the individuals
whose exposures X are changed from one level to the next
by the genetic instrument.
More precisely, let YiðjÞ denote the potential outcome
for subject i obtained by setting, possibly contrary to fact,
the exposure Xi ¼ j. Moreover let Xi ð0Þ and Xi ð1Þ be the
possibly counterfactual values of the exposure obtained by
setting the binary instrument to 0 and 1 respectively. Then
the LATE at exposure level j is defined as
sj ¼ E½YiðjÞ  Yiðj 1Þ jXi ð1Þ j > Xi ð0Þ
that is, the average treatment effect among those whose ex-
posure would be at least j if their instrument were set to 1,
and whose exposure would be less than j if their instrument
were set to 0. Identification of LATEs requires the further
assumption of monotonicity, that is either Xi ð1Þ Xi ð0Þ
 0 or Xi ð1Þ Xi ð0Þ 0 for all subjects i, implying that
the instrument either does not decrease the exposure in all
subjects, or does not increase it in all subjects.
If we could estimate the LATEs sj then testing them for
equality would provide a direct test of linearity of the causal
effect. Here we propose an assumption that allows this to be
performed. Assume that the causal effect of the instrument
on the discretized exposure is exactly 1 in each subject:
Xi ð1Þ Xi ð0Þ ¼ 18i:
This is a stronger version of the monotonicity assump-
tion. In fact, this assumption will hold if the first-stage
linear model is a true structural model for X, with no un-
measured confounders of the G-X association, or modifiers
of the effect of G on X. Under this assumption (and noting
that X has been rescaled so that a one unit change in X
corresponds to the expected exposure change with geno-
type), every subject contributes to a LATE, since for every i
there is a j such that Xi ð1Þ j > Xi ð0Þ, in fact
Xi ð1Þ ¼ j ¼ Xi ð0Þ þ 1. That is, the instrument moves each
subject from one level of X to the next: in the randomized
trials terminology, all subjects are compliers.
It is now possible to assign each subject to the
estimation of a LATE, based on the observed data.
Figure 1. Directed acyclic graphs encoding a) the standard Mendelian
randomization assumptions: (i) G is associated with X, (ii) G is not asso-
ciated with confounders U of the X-Y association, and (iii) G affects Y
only via its association with X; (b) how these assumptions are affected
by the discretization of X in the proposed non-linear Mendelian ran-
domization approach.
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Since Xi ð1Þ ¼ j ¼ Xi ð0Þ þ 1 if and only if Xi ¼ j and
Gi ¼ 1 or Xi ¼ j 1 and Gi ¼ 0, we can write the LATE as
sj ¼ E½YiðjÞ  Yiðj 1Þ jXi ð1Þ j > Xi ð0Þ
¼ E½YiðjÞ jXi ¼ j;Gi ¼ 1 _Xi ¼ j 1;Gi ¼ 0
E½Yiðj 1Þ jXi ¼ j;Gi ¼ 1 _Xi ¼ j 1;Gi ¼ 0
¼ E½Y jXi ¼ j;Gi ¼ 1  E½Y jXi ¼ j 1;Gi ¼ 0
which may be estimated using ordinary linear regression
(possibly with adjustment for relevant covariates) restricted
to the subjects having Xi ¼ j and Gi ¼ 1 or Xi ¼ j 1 and
Gi ¼ 0.
Having estimated a LATE (with its standard error) for
each level of X, the estimates may be tested for equality
using standard methods of meta-analysis. In particular, we
use meta-regression to test for a linear trend in the LATEs.
A linear model relating LATEs to the exposure levels
EðsjÞ ¼ c1 þ c2j
would apply if the underlying causal model were quadratic
EðYÞ ¼ c0 þ c1jþ 12c2j2:
The coefficient c2 is zero if the LATEs are equal, which is
the case when the causal effect of X on Y is linear. Then
the mean LATE, calculated by fixed-effects meta-analysis
of the estimated LATEs, is an alternative measure of the
linear causal effect of X. Rejection of c2 ¼ 0 implies a non-
linear causal effect; a quadratic form is not directly implied
but such a model could be hypothesized, up to its intercept
term, from the fitted meta-regression. The estimation of
a linear model relating LATEs to the exposure levels is a
simple but powerful way to investigate departures from
linearity, as any such departures are captured by a single
parameter. However, alternative models could be fitted to
characterize the dose-response relationship more flexibly.
For example, a piecewise constant model relating the
LATEs to the exposure levels would correspond to a linear
spline model relating the exposure to the outcome. This
could be detected by a test of Cochran’s Q on the estimated
LATEs.
This procedure requires rescaling of X by the effect size
bXG of the instrument. However the true value of bXG is
unknown and it must be estimated. To account for sam-
pling uncertainty in b^XG we nest the entire LATE and
meta-regression procedure within a bootstrap resampling
procedure, using 10 000 bootstrap samples, to obtain
proper confidence intervals on the meta-regression esti-
mates c^1; c^2. Our procedure for testing departure from
linearity of the causal effect of X on Y is summarized in
Box 1.
Beyond a test for departure from linearity, we are inter-
ested in identifying the way the causal effect changes with
increasing alcohol consumption and, in particular, the
nadir of the curve which could be conceived as an ‘optimal’
level of consumption regarding cardiovascular traits. As
we cannot estimate the intercept term in the fitted quad-
ratic model, we cannot predict the absolute value of the
outcome for a given level of alcohol consumption, so we
focus on the difference in outcome relative to zero alcohol
consumption. For those outcomes with evidence of non-
linearity, we predict this at four values of alcohol con-
sumption (3.04, 12.15, 31.90 and 84.52 units/week),
which are the medians of observed values in the categories
representing low (>0–7 units/week), moderate (7–21 units/
week), heavy (21–70 units/week) and very heavy (70þ
units/week) alcohol consumption in the analysis of Holmes
Box 1. Summary of proposed method for testing for a non-linear causal effect
1. For the observed data and for each of K bootstrap samples:
1.1 Regress X on G for all subjects, giving estimated regression coefficient b^XG
1.2 Discretize X into units of b^XG, that is derive the discrete variable X
 ¼ X
b^XG
j k
1.3 For each discrete value of j:
1.3.1 Regress Y on X using only the subjects for which Xi ¼ j and Gi ¼ 1, or X0i ¼ j 1 and Gi ¼ 0. Among
these subjects there is no variation in X that is not explained by G.
1.3.2 This yields s^j, the estimated local average treatment effect (LATE) for level j of X
1.3.3 Rescale s^j by b^XG to the original scale of X
1.4 Obtain the mean LATE by fixed-effects meta-analysis of s^j
1.5 Meta-regress s^j on j to obtain the intercept and slope of the LATEs, corresponding to a quadratic causal model.
2. Obtain empirical confidence intervals on the mean LATE and the LATE intercept and slope from the bootstrap
samples.
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et al.13 By differentiation of the hypothesized quadratic
function, we estimate three additional features of the
curve: (i) the ‘optimal’ level of alcohol consumption; (ii)
the difference in outcome at the optimal alcohol consump-
tion relative to zero alcohol consumption; and (iii) the level
of alcohol consumption required to have an outcome level
equivalent to that at zero alcohol consumption.
Confidence intervals for all the estimates are obtained by
nesting the estimation within the bootstrap resampling
procedure outlined above. In the bootstrap samples we left
truncated the nadir of alcohol consumption at zero.
All analyses were conducted using R version 2.13.27
Simulations
We conducted simulations to assess the proposed approach
in terms of bias and coverage under various data-generat-
ing models. Full details and results are given in the
Supplementary data, available at IJE online. In brief, we
simulated data in which there was no causal X-Y associ-
ation, in which the association was linear and in which
there was a quadratic causal association, allowing
throughout for quadratic effects of confounders. We as-
sessed robustness to the assumption of individual-level
homogeneity of the genetic effect using additional simula-
tions of bXG heterogeneity and G-U interaction at both the
individual and subgroup levels.
We observed that the LATE estimates were essentially
unbiased with generally good coverage properties under
null, linear and quadratic models, and that the test for a
non-linear effect was slightly conservative. Together the
results suggest that this method is a useful extension to
standard approaches in the non-linear setting. Reasonable
levels of individual-level heterogeneity in bXG or between-
subgroup heterogeneity in bXG were not found to lead to
significant bias in the estimates. High levels of interaction
between G and U led to bias in the estimates, but such
interactions may be unlikely in practice.
Results
We investigated the potential non-linear effects of log-
alcohol on each of the outcomes in the Alcohol-ADH1B
Consortium using the proposed procedure. Some issues
relating to the inclusion of multiple studies in the
Consortium are discussed in the Supplementary data, avail-
able at IJE online.
Age- and sex-adjusted study-specific estimates of the
association between rs1229984 and log-alcohol are pre-
sented in Figure S17 of the Supplementary data, available
at IJE online. These study-specific estimates have (inverse-
variance-weighted) mean 0.235 and standard deviation
(SD) 0.121, indicating some degree of between-study vari-
ability. However, in our simulations (see Supplementary
data, available at IJE online) a similar degree of heterogen-
eity between known subgroups (scenario ‘f’ with c ¼ 0:1)
was not found to result in bias to either the LATE intercept
or slope, with slightly conservative confidence intervals for
each.
To examine whether G¼ rs1229984 is a valid instru-
ment for discretized X, assuming that it is valid for the
continuous measure X¼ log-alcohol, we examined the
correlation between G and the remainder XX; these
should be independent for G to be a valid instrument for
X. We observed a weak but significant correlation
(Pearson’s r¼0.013, 95% CI: 0.020, 0.006). We
hypothesized that this residual correlation was due to the
large number of individuals reporting drinking zero weekly
units of alcohol (log-alcohol¼0), because these individuals
have a residual XX ¼ 0 and are also more likely to
have G¼ 0. When individuals with log-alcohol¼0 were
excluded from the analysis, the correlation between G and
the remainder XX was close to zero (Pearson’s
r¼ 0.001, 95% CI: 0.007, 0.009). We therefore re-
analysed the data after excluding individuals with log-
alcohol¼ 0, but obtained very similar results to those from
the full sample. Because it is necessary to retain individuals
reporting zero drinking to meet the objectives of the ana-
lysis, we only report results using the full sample.
The results of the LATE-based analysis for each of the
outcomes are presented in Table 1 along with the standard
linear IV analysis. We illustrate our approach in more de-
tail using SBP as an example, following the steps in Box 1.
We estimated b^XG ¼ 0:244 assuming a common genetic
effect across all studies. Discretizing log-alcohol into units
of 0.244 gave an integer exposure X with range
[26,0]. We then estimated the LATE at each value of X.
For example, for j ¼ 11 [corresponding to a log-alcohol of
110.244¼ 2.684, or exp(2.684) – 1¼ 13.6 units/
week] we selected the subjects with X ¼ 11 and
rs1229984¼1, or X ¼ 12 and rs1229984¼ 0. Linear re-
gression of SBP on X, on these subjects only, and adjusting
for study, age and sex, gave s11 ¼ 1:55; that is, in sub-
jects whose X was changed from 12 to 11 by the SNP,
their SBP was decreased by 1.55 mmHg.
Rescaling by b^XG ¼ 0:244, subjects whose log-
alcohol was changed from 12 0:244 ¼ 2:928 to
11 0:244 ¼ 2:684 [i.e. whose weekly units of alcohol
consumption was changed from exp(2.928) – 1¼ 17.7 to
exp(2.684) – 1¼13.6] by the SNP had their SBP
decreased by 1.55 mmHg. Alternatively, a one-unit in-
crease in log-alcohol at this level of alcohol consumption
[e.g. from 2.684 to 3.684, or from exp(2.684) – 1¼ 13.6
to exp(3.684) – 1¼38.8 units/week—a considerable
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increase] was associated with an increase in SBP of 1:55=
0:244 ¼ 6:35 mmHg.
The full graph of estimated LATEs for SBP is shown in
Figure 2. Negative LATEs represent decreasing SBP with
log-alcohol whereas positive LATEs represent increasing
SBP, so a LATE trend crossing zero from negative to posi-
tive indicates a nadir. Fixed-effects meta-analysis of these
effects gave a mean LATE of 4.9 (95% CI: 2.6, 7.5), which
is effectively a complier average treatment effect and simi-
lar to the linear IV estimate of 5.2 (95% CI: 3.2, 7.3).
Meta-regression of the estimated LATEs on X gave a
slope of 3.3 (95% CI: 1.0, 5.5). This provided strong evi-
dence (Z-test P¼0.004) that the LATEs were not constant
across values of log-alcohol; that is, there was a non-linear
association between log-alcohol and SBP.
Full results for the remaining outcomes are provided in
Table 1. As indicated by the LATE slope, there was evi-
dence of a non-linear causal effect for SBP, non-HDL-C,
BMI, WC and CRP (all P 0.01). For other outcomes
there was no evidence of a non-linear causal effect (HDL-
C, IL-6 and triglycerides, all P> 0.4, though note that
power is lower for IL-6 due to the relatively small sample
size). In these cases we recommend that the linear IV re-
sults are employed, as fewer assumptions are required in
their estimation. It should also be noted that the linear IV
estimates and the mean LATEs were similar for each of the
outcomes, albeit with the latter having wider CIs.
Table 2 shows the predicted difference in each outcome
relative to zero alcohol consumption for 3.04, 12.15, 31.90
and 84.52 units/week of alcohol consumption under the fit-
ted quadratic functions. All outcomes, with the exception
of SBP, were predicted to be lower at 3.04 units/week
(‘low’ alcohol consumption) than at zero alcohol consump-
tion, though each confidence interval included the possibil-
ity of no true difference. By 31.90 units/week (‘heavy’
alcohol consumption) all outcomes were predicted to be
higher than at zero alcohol consumption, though each con-
fidence interval, with the exception of SBP, again included
the possibility of no true difference. By 84.52 units/week
(‘very heavy’ alcohol consumption) all the confidence inter-
vals excluded the possibility of no true difference.
Table 1. Comparison of linear and non-linear instrumental variable estimates for selected cardiovascular traits in the Alcohol-
ADH1B Consortium
Outcome n Linear IV approach Non-linear IV approach
Mean LATE LATE intercept LATE slope
Estimate 95% CIa Estimate 95% CIa Estimate 95% CIa Estimate 95% CIa Pb
SBP (mmHg) 78172 5.20 3.2, 7.3 4.90 2.6, 7.5 2.20 7.5, 3.4 3.30 1.0, 5.5 0.004
Non-HDL-C (mmol/l) 60140 0.13 0.02, 0.28 0.25 0.06, 0.45 0.54 0.94, 0.120 0.37 0.19, 0.55 <0.001
HDL-C (mmol/l) 60227 0.02 0.07, 0.03 0.01 0.07, 0.06 0.02 0.15, 0.14 0.00 0.06, 0.06 0.910
BMI (kg/m2) 79454 0.70 0.2, 1.2 1.00 0.4, 1.5 1.00 2.5, 0.3 0.90 0.3, 1.4 0.002
WC (cm) 57172 2.80 1.3, 4.4 2.70 1.1, 4.5 1.80 5.8, 1.9 2.00 0.6, 3.6 0.010
CRPc (mg/l) 63367 0.17 0.03, 0.31 0.18 0.03, 0.38 0.39 0.77, 0.03 0.26 0.10, 0.43 0.001
IL-6c (pg/ml) 23535 0.30 0.16, 0.45 0.35 0.10, 0.53 0.10 0.24, 0.85 0.13 0.34, 0.29 0.410
TGc (mmol/l) 63667 0.01 0.06, 0.07 0.01 0.09, 0.07 0.04 0.15, 0.21 0.02 0.10, 0.06 0.670
SBP, systolic blood pressure; Non-HDL-C, non high-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; BMI, body mass index; WC,
waist circumference; CRP, C-reactive protein; IL-6, interleukin 6; TG, triglycerides.
aDerived using 10 000 bootstrap samples.
bApproximate Z-test using the bootstrap standard error.
cLog-transformed prior to analysis.
Figure 2. Local average treatment effects (LATEs) of log(weekly units of
alcohol þ 1) on systolic blood pressure. Circular markers are LATEs;
bars are 95% pointwise confidence intervals; dashed line is estimated
mean LATE; solid line is estimated linear LATE trend; dotted line is lin-
ear IV estimate using the ratio method (virtually indistinguishable from
the estimated mean LATE).
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Table 2 also shows the additional estimated features of
the hypothesized quadratic functions. For all outcomes,
the optimal level of alcohol consumption was estimated to
be greater than zero, ranging from 1.0 units/week (SBP) to
3.5 units/week (CRP). However, only for non-HDL-C did
the confidence interval exclude the possibility that zero
consumption may be optimal. Correspondingly, the esti-
mated difference in outcome at the optimal alcohol con-
sumption level relative to zero consumption was negative
for each outcome, though only for non-HDL-C did the
confidence interval exclude the possibility of no true differ-
ence. The level of alcohol consumption required to have an
outcome level equivalent to that at zero consumption was
estimated as ranging from 2.8 units/week (SBP) to 19.4
units/week (CRP), though for all outcomes the confidence
intervals were very wide. These results are illustrated for
non-HDL-C, for which the strongest evidence of non-
linearity was observed, in Figure 3. However, the precise
values of our quantitative results should be interpreted
with some caution as the quadratic causal model that we
fit may not be sufficiently flexible to fully characterize the
dose-response relationship.
Discussion
We have proposed a method based on estimating LATEs
that allows a basic estimation of local causal effects of a
continuous exposure when using a binary instrument. Our
method requires an assumption of homogeneous individual
treatment effects of the instrument on the exposure, but
our simulations found the estimates obtained under our ap-
proach to be largely unbiased and with good coverage
properties under a variety of heterogeneous effects of in-
strument on exposure.
The local effects we estimate are within discretized units
of the exposure, with the size of those units depending on
the gene-exposure association. This is not a scale with a
generally useful interpretation, and different genetic instru-
ments could lead to different discrete units with different
definitions of local causal effects. We therefore emphasize
Table 2. Predicted difference in cardiovascular traits relative to zero alcohol consumption at several levels of alcohol consump-
tion and predicted curve features in the Alcohol-ADH1B Consortium. Only calculated for traits with evidence of non-linearity
Outcome Difference in outcome (95% CIa) Level of alcohol
consumption
at nadir
(units/week)
(95% CIa)
Difference in
outcome at
optimal alcohol
consumption
(95% CIa)
Level of alcohol
consumption
with outcome
equal to that at
zero (units/week)
(95% CIa)
3.04
units/weekc
12.15
units/weekc
31.90
units/weekc
84.52
units/weekc
SBP (mmHg) 0.1 (5.5, 6.1) 5.2 (2.6, 13.9) 12.4 (3.4, 22.1) 22.8 (12.2, 34.6) 1.0 (0.0, 3.6) 0.7 (5.4, 0.0) 2.8 (0.0, 19.6)
Non-HDL-C
(mmol/l)
0.39 (0.79, 0.06) 0.15 (0.72, 0.47) 0.40 (0.28, 1.10) 1.30 (0.45, 2.16) 3.2 (0.7, 6.0) 0.39 (0.85, 0.03) 16.9 (2.1, 48.2)
BMI (kg/m2) 0.6 (2.2, 0.8) 0.2 (2.0, 2.1) 1.6 (0.8, 3.8) 3.9 (1.2, 6.3) 2.3 (0.0, 6.0) 0.6 (2.3, 0.0) 10.1 (0.0, 48.4)
WC (cm) 0.6 (4.7, 3.5) 1.9 (3.9, 7.8) 5.7 (0.6, 12.5) 11.5 (4.5, 19.2) 1.5 (0.0, 5.4) 0.8 (4.9, 0.0) 5.3 (0.0, 37.4)
CRPb (mg/l) 0.29 (0.68, 0.15) 0.15 (0.68, 0.50) 0.22 (0.37, 0.95) 0.83 (0.15, 1.69) 3.5 (0.0, 7.2) 0.30 (0.75, 0.00) 19.4 (0.0, 66.0)
SBP, systolic blood pressure; Non-HDL-C, non high-density lipoprotein cholesterol; BMI, body mass index; WC, waist circumference; CRP, C-reactive
protein.
aDerived using 10 000 bootstrap samples.
bLog-transformed prior to analysis.
cWeekly units of alcohol values are medians of observed values in categories representing low (1–7 units/week), moderate (7–21 units/week), heavy (21–70
units/week) and very heavy (70þ units/week) alcohol consumption in the analysis of Holmes et al.13
Figure 3. Predicted difference in non high-density lipoprotein choles-
terol (non-HDL-C) relative to zero alcohol consumption across the range
of values of observed alcohol consumption, with estimated optimal
level of alcohol consumption (3.2 (95% confidence interval (CI): 0.7, 6.0)
units/week), estimated difference in non-HDL-C relative to zero alcohol
consumption at optimal level (0.39 (95% CI: 0.85, 0.03) mmol/l),
and estimated level of alcohol consumption with the same level of non-
HDL-C as at zero (16.9 (95% CI: 2.1, 48.2) units/week) indicated.
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the ability to test for a non-linear causal effect and draw
qualitative conclusions about the shape of that effect, and
we suggest that a strictly quantitative interpretation of the
estimated parameters should be viewed with some caution.
Further work is required in investigating alternative mod-
els relating the LATEs to the exposure levels in order to
provide greater flexibility for characterizing the dose-
response relationship.
Using this approach, we detected evidence for a non-
linear causal effect of log-alcohol on several cardiovascular
traits in a large collaborative study, which would not have
been possible using standard IV approaches. For each out-
come that exhibited evidence of a non-linear causal effect,
our results suggested that the level of alcohol consumption
associated with the lowest value of the cardiovascular
traits to lie between 1.0 and 3.5 units/week. However, only
for non-HDL-C do we have strong evidence that the opti-
mal level of consumption truly differs from zero.
As the cardiovascular traits considered in this analysis
were observed concurrently with the level of alcohol con-
sumption in many of the studies within the ADH1B
Consortium, a conventional analysis would be at risk of
bias due to reverse causality (for example, someone with
high SBP reducing their alcohol intake so that they are
observed to have a low level of consumption). A
Mendelian randomization analysis removes the possibility
of such reverse causality, which is a significant strength of
the present study.
For our estimated effects to be interpreted causally we
need the standard assumptions underlying MR analysis to
hold. Of particular concern in the present application is
the exclusion restriction that G has no effect on Y other
than through X. We have only considered one aspect of al-
cohol consumption (weekly units), but if the polymorph-
ism in ADH1B reduces alcohol consumption generally,
then other aspects, such as frequency of binge drinking,
may also be associated with the instrument.19 If such other
aspects have a causal effect on the outcome independently
of weekly units, then the exclusion restriction would not
hold. The strong correlation between weekly units and
other aspects of alcohol consumption makes a significant
violation of this assumption unlikely. However, further re-
search is required in this area.
Although we limited our analyses to individuals of
European descent and adjusted for study in all our ana-
lyses, there may be residual population stratification of the
variant which could lead to backdoor pathways from the
instrument to the outcome. The restriction to individuals
of European descent may also reduce the generalizability
of our findings beyond such populations.
An inherent aspect of our approach is the need for a
large sample with a sufficiently strong association between
the gene and the exposure. If the gene-exposure association
is very weak, then the exposure will be discretized into
many bins, none of which will contain sufficient subjects
for the LATEs to be estimated. Many MR studies are now
conducted on large samples in order to improve power to
detect causal effects, but our approach requires large sam-
ples across a sufficient range of the exposure in order to de-
tect non-linearities. This problem is compounded when
studying binary outcomes, as each bin should contain a
sufficient number of events. Therefore we have restricted
our attention to continuous outcomes in this paper, but we
recognize that here the key interest is in the nature of the
causal relationship with cardiovascular disease events,
which cannot be readily deduced from the associations
with different risk factors. Further work in this area is
required.
We believe our method is useful for inferring departure
from linearity when only a binary instrument is available.
Although there is clearly greater scope for bias than in
standard IV analysis, we did not infer non-linear effects for
several of the cardiovascular outcomes we considered, sug-
gesting some degree of specificity using our method. More
robust inference of non-linear causal effects may be pos-
sible from polychotomous or continuous instruments, such
as gene scores constructed from multiple SNPs.28,29 Such
instruments will allow the identification of non-linear
models with many parameters, though IV estimation of
parametric non-linear models has been found to be de-
pendent on the choice of parametric model.23 A further
key issue is whether the exposures predicted by those in-
struments cover a sufficient range to capture the non-linear
features of the causal effects. If this is not the case, then it
may be necessary to pursue approaches based on local ef-
fects, similar to the one for binary instruments that we
have discussed here.
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